Results 31 to 40 of about 2,979 (199)

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence

European Psychiatry, 2023
Introduction There is an increasing need to understand the effectiveness of novel medications in real-world context since despite being the gold standard, double-blind trials have their own limitations as well.
E. Rancans, Z. B. Dombi, R. Csehi, G. Németh   +3 more
doaj   +1 more source

Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases

, 2021
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3 receptors with preferential binding to the D3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A.
Orsolini, Laura, Olivieri, Luigi, Serroni, Nicola, Iasevoli, Felice, Lauretis, Ida De, Berardis, Domenico De, Cottura, Paolo, Alessandrini, Marco, Trotta, Sabatino, Giardini, Agostina, Vellante, Federica, Rapini, Gabriella, Giannantonio, Massimo Di, Fornaro, Michele   +13 more
core   +2 more sources

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials

Frontiers in Psychiatry, 2021
Bipolar disorder (BD) is chronic psychiatric disorder associated with significant impairment in psychosocial functioning and quality of life. Although current pharmacological treatments for BD have improved its clinical management, many patients do not ...
André Do, Kamyar Keramatian, Ayal Schaffer, Lakshmi Yatham   +3 more
doaj   +1 more source

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment

Consortium Psychiatricum, 2020
Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in ...
Aleksandr M. Reznik, Aleksandr L. Arbuzov, Sergey P. Murin, Aleksey V. Pavlichenko   +3 more
doaj   +1 more source

Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report

BMC Psychiatry, 2023
Background Cariprazine is a third-generation antipsychotic with a unique mechanism of action. It functions as a partial agonist with high affinity for dopamine D2 and D3 and serotonin 5-HT1A receptors, an antagonist for 5-HT2A (moderate affinity) and 5 ...
Polona Rus Prelog, Anja Kokalj Palandacic   +1 more
doaj   +1 more source

Case series: Cariprazine in early-onset schizophrenia

Frontiers in Psychiatry, 2023
IntroductionNegative symptoms are part of the clinical manifestations of schizophrenia and their presence is associated with a poorer prognosis, significantly limited vocational opportunities, impaired quality of life and social functioning.
Elena Ivanova, Elena Ivanova, Desislava Maslinkova, Desislava Maslinkova, Nadia Polnareva, Vihra Milanova   +5 more
doaj   +1 more source

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

Frontiers in Psychiatry, 2022
BackgroundBecause of limited efficacy of antipsychotics against negative symptoms in schizophrenia new drugs with wider spectrums of clinical efficacy are very desirable.
Stanislav V. Ivanov, Stanislav V. Ivanov, Anatoly B. Smulevich, Anatoly B. Smulevich, Evgeniya I. Voronova, Evgeniya I. Voronova, Kausar K. Yakhin, Tangyul Z. Beybalaeva, Alena A. Katok   +8 more
doaj   +1 more source

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia

European Psychiatry, 2021
Introduction Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS).
I. Laszlovszky, Z.B. Dombi, Á. Balogh, Á. Barabássy, G. Vass, B. Szatmári, G. Németh   +6 more
doaj   +1 more source

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials

European Psychiatry, 2022
Introduction Chronic schizophrenia patients are experiencing persistent and severe illness for more than 15-20 years and are usually suffering from long-term negative symptoms.
P. Falkai, Z. Dombi, K. Acsai, Á. Barabássy, G. Németh   +4 more
doaj   +1 more source

Cariprazine and Akathisia, Restlessness, and Extrapyramidal Symptoms in Patients with Bipolar Depression

, 2021
BACKGROUND: Akathisia is a neuropsychiatric syndrome that is commonly related to the use of dopamine receptor antagonists/partial agonists. The characteristics of cariprazine-related akathisia, restlessness, and extrapyramidal symptoms (EPS) were ...
Earley, Willie R, Patel, Mehul D, Barabássy, Ágota, Hankinson, Arlene, Citrome, Leslie, Yatham, Lakshmi N, Arlene Hankinson, Lakshmi N. Yatham, Ágota Barabássy, Leslie Citrome, Mehul D. Patel, Willie R. Earley   +11 more
core   +1 more source